Lab-based IVD Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

The global lab-based in vitro diagnostics (IVD) market remains a foundational pillar of modern healthcare, driven by rising chronic disease prevalence, infectious disease outbreaks, and the global shift toward precision medicine. According to the latest industry assessment, the market was valued at USD 42.42 billion in 2024, supported by strong diagnostic demand across hospitals and clinical laboratories. The market is expected to increase to USD 44.85 billion in 2025, eventually reaching USD 66.41 billion by 2032, advancing at a CAGR of 5.8% throughout 2025-2032.

North America dominated the global market with 39.39% share in 2024, attributed to its advanced healthcare infrastructure, high diagnostic testing rates, and the presence of leading companies such as Roche, Abbott, Thermo Fisher Scientific, and BD. The rising need for rapid, reliable, and high-precision diagnostic results is accelerating investment in automated testing platforms, molecular diagnostics, and next-generation sequencing technologies.

Market Drivers

A key driver for the lab-based IVD market is the growing global burden of chronic and infectious diseases. According to WHO, 8.2 million people were diagnosed with tuberculosis (TB) in 2023, up from 7.5 million in 2022, indicating heightened screening needs worldwide. Additionally, WHO reported in 2024 that 254 million individuals were living with hepatitis B and 50 million with hepatitis C, further boosting demand for routine laboratory testing.

Growing awareness of early disease detection, increasing screening programs, and public health initiatives-such as the WHO's 2023 Essential Diagnostics List (EDL)-continue to improve access to lab-based diagnostic tools across emerging and developed markets. The expanding geriatric population further contributes to diagnostic demand, as elderly individuals are more susceptible to chronic and infectious diseases requiring regular monitoring.

Market Restraints

Despite strong growth potential, the market faces challenges from unfavorable reimbursement policies in several emerging markets. The high cost of genetic and molecular diagnostic tests limits adoption in regions such as Africa, Brazil, and parts of Asia. In China, reimbursement occurs at the provincial level with differing codes, creating delays and inconsistency in diagnostic uptake. These factors collectively restrict large-scale penetration of advanced IVD systems.

Market Opportunities

Major opportunities lie in the rising adoption of molecular diagnostics, including next-generation sequencing (NGS) and PCR-based technologies. Companies are increasingly pursuing FDA approvals and global regulatory certifications to strengthen their molecular testing portfolios. For example, DiaSorin S.p.A. received FDA approval for its Simplex COVID-19 & Flu A/B Direct assay in 2023, expanding its high-value molecular pipeline. The shift from traditional diagnostics to molecular precision tools opens pathways for improved cancer detection, viral load testing, and genetic screening.

Market Trends

A significant trend in the lab-based IVD market is the rising integration of automation and digitalization in laboratory workflows. Automated PCR systems, AI-enabled analyzers, and advanced hematology systems are improving test accuracy and turnaround time. In April 2025, Seegene Inc. announced development of its next-generation automation platform, CURECA, designed to streamline PCR testing processes globally.

Additionally, several companies are investing in personalized diagnostic solutions. In February 2024, Quest Diagnostics launched MelaNodal Predict, an AI-supported gene expression test for personalized melanoma treatment guidance.

Segmental Overview

By Product Type

Reagents & consumables dominated the market in 2024 due to increasing regulatory approvals and growing test volumes. The instruments segment is projected to grow steadily through 2032 with rising adoption of rapid testing devices and advanced PCR systems.

By Technique

Immunodiagnostics led the market in 2024, supported by new assay launches such as Roche's Elecsys HBeAg quant test. The molecular diagnostics segment held the second-largest share, fueled by the growing number of PCR-based solutions and next-generation sequencing applications.

By Sample Type

Blood-based tests dominated the market in 2024 and are expected to grow at the highest CAGR due to widespread usage in acute infections, oncology, and chronic disease assessments.

By Application

Infectious diseases remained the leading segment in 2024, supported by high global burdens of TB, HIV, and hepatitis. Oncology is expected to grow at the second-highest CAGR due to rising cancer cases and the launch of highly sensitive cancer assays.

By End-User

Clinical laboratories dominated the IVD market in 2024, driven by high patient volumes and advanced testing capabilities. Hospitals continued to support significant demand due to increasing hospitalization rates for chronic diseases.

Regional Insights

North America

North America generated USD 16.71 billion in 2024, maintaining market leadership through advanced healthcare standards and continuous product approvals from the FDA.

Europe

Europe ranked second in 2024, supported by chronic disease prevalence and strong innovation momentum from Siemens Healthineers, Sysmex, and Roche.

Asia Pacific

Asia Pacific is expected to record the fastest CAGR through 2032 due to rising early-diagnosis awareness and increased product launches, including Abbott's Alinity i immunoassay module in 2024.

Latin America & Middle East & Africa

These regions show steady growth supported by rising TB cases and increasing adoption of automated chemistry and hematology analyzers.

Conclusion

With the market rising from USD 42.42 billion in 2024 to USD 66.41 billion in 2032, the global lab-based IVD industry is set for significant expansion. Growing infectious disease screening, rapid adoption of molecular diagnostics, automation improvements, and strategic partnerships across companies will continue shaping the future of clinical diagnostics worldwide.

Segmentation By Product Type

Instruments
Reagents & Consumables

By Technique

Immunodiagnostics
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Fluorescence Immunoassay (FIA)
- Rapid test
- Others
Clinical Chemistry
- Electrolyte Panel
- Basic and Comprehensive Metabolic Panels
- Liver Tests
- Renal Tests
- Lipid Panel
- Others
Molecular Diagnostics
- Polymerase Chain Reaction (PCR)
- In Situ Hybridization
- DNA Sequencing & Next-Generation Sequencing
- Others
Hematology
Others

By Sample Type

Blood
Urine
Saliva
Tissue
Others

By Application

Infectious Diseases
Cardiology
Oncology
Gastroenterology
Allergy
Autoimmunity
Prenatal Screening
Others

By End-user

Hospitals
Clinical Laboratories
Others

By Region

North America (By Product Type, By Technique, By Sample Type, By Application, By End-user, and By Country/Sub-Region)
- U.S.
- Canada
Europe (By Product Type, By Technique, By Sample Type, By Application, By End-user, and By Country/Sub-Region)
- Germany
- U.K.
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
Asia Pacific (By Product Type, By Technique, By Sample Type, By Application, By End-user, and By Country/Sub-Region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
Latin America (By Product Type, By Technique, By Sample Type, By Application, By End-user, and By Country/Sub-Region)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa (By Product Type, By Technique, By Sample Type, By Application, By End-user, and By Country/Sub-Region)
- GCC
- South Africa
Rest of Middle East & Africa

Product Code: FBI112985

Table of Content

1. Introduction

1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends

4. Key Insights

4.1. Prevalence of Key Diseases, by Key Countries/Sub-regions, 2023/2024
4.2. Technological Advancements in Lab-based IVD Products
4.3. New Product Launches, by Key Players
4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

5. Global Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

5.1. Market Analysis, Insights and Forecast - By Product Type
- 5.1.1. Instruments
- 5.1.2. Reagents & Consumables
5.2. Market Analysis, Insights and Forecast - By Technique
- 5.2.1. Immunodiagnostics
  - 5.2.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
  - 5.2.1.2. Fluorescence immunoassay (FIA)
  - 5.2.1.3. Rapid test
  - 5.2.1.4. Others
- 5.2.2. Clinical Chemistry
  - 5.2.2.1. Electrolyte Panel
  - 5.2.2.2. Basic and Comprehensive Metabolic Panels
  - 5.2.2.3. Liver Tests
  - 5.2.2.4. Renal Tests
  - 5.2.2.5. Lipid Panel
  - 5.2.2.6. Others
- 5.2.3. Molecular Diagnostics
  - 5.2.3.1. Polymerase Chain Reaction (PCR)
  - 5.2.3.2. In Situ Hybridization
  - 5.2.3.3. DNA Sequencing & Next-Generation Sequencing
  - 5.2.3.4. Others
- 5.2.4. Hematology
- 5.2.5. Others
5.3. Market Analysis, Insights and Forecast - By Sample Type
- 5.3.1. Blood
- 5.3.2. Urine
- 5.3.3. Saliva
- 5.3.4. Tissue
- 5.3.5. Others
5.4. Market Analysis, Insights and Forecast - By Application
- 5.4.1. Infectious Diseases
- 5.4.2. Cardiology
- 5.4.3. Oncology
- 5.4.4. Gastroenterology
- 5.4.5. Allergy
- 5.4.6. Autoimmunity
- 5.4.7. Prenatal Screening
- 5.4.8. Others
5.5. Market Analysis, Insights and Forecast - By End-user
- 5.5.1. Hospitals
- 5.5.2. Clinical Laboratories
- 5.5.3. Others
5.6. Market Analysis, Insights and Forecast - By Region
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia Pacific
- 5.6.4. Latin America
- 5.6.5. Middle East & Africa

6. North America Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

6.1. Market Analysis, Insights and Forecast - By Product Type
- 6.1.1. Instruments
- 6.1.2. Reagents & Consumables
6.2. Market Analysis, Insights and Forecast - By Technique
- 6.2.1. Immunodiagnostics
  - 6.2.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
  - 6.2.1.2. Fluorescence immunoassay (FIA)
  - 6.2.1.3. Rapid test
  - 6.2.1.4. Others
- 6.2.2. Clinical Chemistry
  - 6.2.2.1. Electrolyte Panel
  - 6.2.2.2. Basic and Comprehensive Metabolic Panels
  - 6.2.2.3. Liver Tests
  - 6.2.2.4. Renal Tests
  - 6.2.2.5. Lipid Panel
  - 6.2.2.6. Others
- 6.2.3. Molecular Diagnostics
  - 6.2.3.1. Polymerase Chain Reaction (PCR)
  - 6.2.3.2. In Situ Hybridization
  - 6.2.3.3. DNA Sequencing & Next-Generation Sequencing
  - 6.2.3.4. Others
- 6.2.4. Hematology
- 6.2.5. Others
6.3. Market Analysis, Insights and Forecast - By Sample Type
- 6.3.1. Blood
- 6.3.2. Urine
- 6.3.3. Saliva
- 6.3.4. Tissue
- 6.3.5. Others
6.4. Market Analysis, Insights and Forecast - By Application
- 6.4.1. Infectious Diseases
- 6.4.2. Cardiology
- 6.4.3. Oncology
- 6.4.4. Gastroenterology
- 6.4.5. Allergy
- 6.4.6. Autoimmunity
- 6.4.7. Prenatal Screening
- 6.4.8. Others
6.5. Market Analysis, Insights and Forecast - By End-user
- 6.5.1. Hospitals
- 6.5.2. Clinical Laboratories
- 6.5.3. Others
6.6. Market Analysis, Insights and Forecast - By Country
- 6.6.1. U.S.
- 6.6.2. Canada

7. Europe Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

7.1. Market Analysis, Insights and Forecast - By Product Type
- 7.1.1. Instruments
- 7.1.2. Reagents & Consumables
7.2. Market Analysis, Insights and Forecast - By Technique
- 7.2.1. Immunodiagnostics
  - 7.2.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
  - 7.2.1.2. Fluorescence immunoassay (FIA)
  - 7.2.1.3. Rapid test
  - 7.2.1.4. Others
- 7.2.2. Clinical Chemistry
  - 7.2.2.1. Electrolyte Panel
  - 7.2.2.2. Basic and Comprehensive Metabolic Panels
  - 7.2.2.3. Liver Tests
  - 7.2.2.4. Renal Tests
  - 7.2.2.5. Lipid Panel
  - 7.2.2.6. Others
- 7.2.3. Molecular Diagnostics
  - 7.2.3.1. Polymerase Chain Reaction (PCR)
  - 7.2.3.2. In Situ Hybridization
  - 7.2.3.3. DNA Sequencing & Next-Generation Sequencing
  - 7.2.3.4. Others
- 7.2.4. Hematology
- 7.2.5. Others
7.3. Market Analysis, Insights and Forecast - By Sample Type
- 7.3.1. Blood
- 7.3.2. Urine
- 7.3.3. Saliva
- 7.3.4. Tissue
- 7.3.5. Others
7.4. Market Analysis, Insights and Forecast - By Application
- 7.4.1. Infectious Diseases
- 7.4.2. Cardiology
- 7.4.3. Oncology
- 7.4.4. Gastroenterology
- 7.4.5. Allergy
- 7.4.6. Autoimmunity
- 7.4.7. Prenatal Screening
- 7.4.8. Others
7.5. Market Analysis, Insights and Forecast - By End-user
- 7.5.1. Hospitals
- 7.5.2. Clinical Laboratories
- 7.5.3. Others
7.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 7.6.1. Germany
- 7.6.2. U.K.
- 7.6.3. France
- 7.6.4. Italy
- 7.6.5. Spain
- 7.6.6. Scandinavia
- 7.6.7. Rest of Europe

8. Asia Pacific Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

8.1. Market Analysis, Insights and Forecast - By Product Type
- 8.1.1. Instruments
- 8.1.2. Reagents & Consumables
8.2. Market Analysis, Insights and Forecast - By Technique
- 8.2.1. Immunodiagnostics
  - 8.2.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
  - 8.2.1.2. Fluorescence immunoassay (FIA)
  - 8.2.1.3. Rapid test
  - 8.2.1.4. Others
- 8.2.2. Clinical Chemistry
  - 8.2.2.1. Electrolyte Panel
  - 8.2.2.2. Basic and Comprehensive Metabolic Panels
  - 8.2.2.3. Liver Tests
  - 8.2.2.4. Renal Tests
  - 8.2.2.5. Lipid Panel
  - 8.2.2.6. Others
- 8.2.3. Molecular Diagnostics
  - 8.2.3.1. Polymerase Chain Reaction (PCR)
  - 8.2.3.2. In Situ Hybridization
  - 8.2.3.3. DNA Sequencing & Next-Generation Sequencing
  - 8.2.3.4. Others
- 8.2.4. Hematology
- 8.2.5. Others
8.3. Market Analysis, Insights and Forecast - By Sample Type
- 8.3.1. Blood
- 8.3.2. Urine
- 8.3.3. Saliva
- 8.3.4. Tissue
- 8.3.5. Others
8.4. Market Analysis, Insights and Forecast - By Application
- 8.4.1. Infectious Diseases
- 8.4.2. Cardiology
- 8.4.3. Oncology
- 8.4.4. Gastroenterology
- 8.4.5. Allergy
- 8.4.6. Autoimmunity
- 8.4.7. Prenatal Screening
- 8.4.8. Others
8.5. Market Analysis, Insights and Forecast - By End-user
- 8.5.1. Hospitals
- 8.5.2. Clinical Laboratories
- 8.5.3. Others
8.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. Australia
- 8.6.5. Southeast Asia
- 8.6.6. Rest of Asia Pacific

9. Latin America Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

9.1. Market Analysis, Insights and Forecast - By Product Type
- 9.1.1. Instruments
- 9.1.2. Reagents & Consumables
9.2. Market Analysis, Insights and Forecast - By Technique
- 9.2.1. Immunodiagnostics
  - 9.2.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
  - 9.2.1.2. Fluorescence immunoassay (FIA)
  - 9.2.1.3. Rapid test
  - 9.2.1.4. Others
- 9.2.2. Clinical Chemistry
  - 9.2.2.1. Electrolyte Panel
  - 9.2.2.2. Basic and Comprehensive Metabolic Panels
  - 9.2.2.3. Liver Tests
  - 9.2.2.4. Renal Tests
  - 9.2.2.5. Lipid Panel
  - 9.2.2.6. Others
- 9.2.3. Molecular Diagnostics
  - 9.2.3.1. Polymerase Chain Reaction (PCR)
  - 9.2.3.2. In Situ Hybridization
  - 9.2.3.3. DNA Sequencing & Next-Generation Sequencing
  - 9.2.3.4. Others
- 9.2.4. Hematology
- 9.2.5. Others
9.3. Market Analysis, Insights and Forecast - By Sample Type
- 9.3.1. Blood
- 9.3.2. Urine
- 9.3.3. Saliva
- 9.3.4. Tissue
- 9.3.5. Others
9.4. Market Analysis, Insights and Forecast - By Application
- 9.4.1. Infectious Diseases
- 9.4.2. Cardiology
- 9.4.3. Oncology
- 9.4.4. Gastroenterology
- 9.4.5. Allergy
- 9.4.6. Autoimmunity
- 9.4.7. Prenatal Screening
- 9.4.8. Others
9.5. Market Analysis, Insights and Forecast - By End-user
- 9.5.1. Hospitals
- 9.5.2. Clinical Laboratories
- 9.5.3. Others
9.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 9.6.1. Brazil
- 9.6.2. Mexico
- 9.6.3. Rest of Latin America

10. Middle East & Africa Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

10.1. Market Analysis, Insights and Forecast - By Product Type
- 10.1.1. Instruments
- 10.1.2. Reagents & Consumables
10.2. Market Analysis, Insights and Forecast - By Technique
- 10.2.1. Immunodiagnostics
  - 10.2.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
  - 10.2.1.2. Fluorescence immunoassay (FIA)
  - 10.2.1.3. Rapid test
  - 10.2.1.4. Others
- 10.2.2. Clinical Chemistry
  - 10.2.2.1. Electrolyte Panel
  - 10.2.2.2. Basic and Comprehensive Metabolic Panels
  - 10.2.2.3. Liver Tests
  - 10.2.2.4. Renal Tests
  - 10.2.2.5. Lipid Panel
  - 10.2.2.6. Others
- 10.2.3. Molecular Diagnostics
  - 10.2.3.1. Polymerase Chain Reaction (PCR)
  - 10.2.3.2. In Situ Hybridization
  - 10.2.3.3. DNA Sequencing & Next-Generation Sequencing
  - 10.2.3.4. Others
- 10.2.4. Hematology
- 10.2.5. Others
10.3. Market Analysis, Insights and Forecast - By Sample Type
- 10.3.1. Blood
- 10.3.2. Urine
- 10.3.3. Saliva
- 10.3.4. Tissue
- 10.3.5. Others
10.4. Market Analysis, Insights and Forecast - By Application
- 10.4.1. Infectious Diseases
- 10.4.2. Cardiology
- 10.4.3. Oncology
- 10.4.4. Gastroenterology
- 10.4.5. Allergy
- 10.4.6. Autoimmunity
- 10.4.7. Prenatal Screening
- 10.4.8. Others
10.5. Market Analysis, Insights and Forecast - By End-user
- 10.5.1. Hospitals
- 10.5.2. Clinical Laboratories
- 10.5.3. Others
10.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 10.6.1. GCC
- 10.6.2. South Africa
- 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

11.1. Global Market Share Analysis (2024)
11.2. Company Profiles
- 11.2.1. F. Hoffmann-La Roche Ltd.
  - 11.2.1.1. Overview
  - 11.2.1.2. Products
  - 11.2.1.3. Financials (Based on Availability)
  - 11.2.1.4. Recent Developments
  - 11.2.1.5. Strategies
  - 11.2.1.6. SWOT,Etc.
- 11.2.2. Abbott
  - 11.2.2.1. Overview
  - 11.2.2.2. Products
  - 11.2.2.3. Financials (Based on Availability)
  - 11.2.2.4. Recent Developments
  - 11.2.2.5. Strategies
  - 11.2.2.6. SWOT,Etc.
- 11.2.3. Thermo Fisher Scientific Inc.
  - 11.2.3.1. Overview
  - 11.2.3.2. Products
  - 11.2.3.3. Financials (Based on Availability)
  - 11.2.3.4. Recent Developments
  - 11.2.3.5. Strategies
  - 11.2.3.6. SWOT,Etc.
- 11.2.4. Sysmex Corporation
  - 11.2.4.1. Overview
  - 11.2.4.2. Products
  - 11.2.4.3. Financials (Based on Availability)
  - 11.2.4.4. Recent Developments
  - 11.2.4.5. Strategies
  - 11.2.4.6. SWOT,Etc.
- 11.2.5. Siemens Healthineers AG
  - 11.2.5.1. Overview
  - 11.2.5.2. Products
  - 11.2.5.3. Financials (Based on Availability)
  - 11.2.5.4. Recent Developments
  - 11.2.5.5. Strategies
  - 11.2.5.6. SWOT,Etc.
- 11.2.6. BD
  - 11.2.6.1. Overview
  - 11.2.6.2. Products
  - 11.2.6.3. Financials (Based on Availability)
  - 11.2.6.4. Recent Developments
  - 11.2.6.5. Strategies
  - 11.2.6.6. SWOT,Etc.
- 11.2.7. QIAGEN
  - 11.2.7.1. Overview
  - 11.2.7.2. Products
  - 11.2.7.3. Financials (Based on Availability)
  - 11.2.7.4. Recent Developments
  - 11.2.7.5. Strategies
  - 11.2.7.6. SWOT,Etc.
- 11.2.8. Bio-Rad Laboratories, Inc.
  - 11.2.8.1. Overview
  - 11.2.8.2. Products
  - 11.2.8.3. Financials (Based on Availability)
  - 11.2.8.4. Recent Developments
  - 11.2.8.5. Strategies
  - 11.2.8.6. SWOT,Etc.
- 11.2.9. Seegene Inc.
  - 11.2.9.1. Overview
  - 11.2.9.2. Products
  - 11.2.9.3. Financials (Based on Availability)
  - 11.2.9.4. Recent Developments
  - 11.2.9.5. Strategies
  - 11.2.9.6. SWOT,Etc.
- 11.2.10. DiaSorin S.p.A.
  - 11.2.10.1. Overview
  - 11.2.10.2. Products
  - 11.2.10.3. Financials (Based on Availability)
  - 11.2.10.4. Recent Developments
  - 11.2.10.5. Strategies
  - 11.2.10.6. SWOT,Etc.
- 11.2.11. Quest Diagnostics Incorporated
  - 11.2.11.1. Overview
  - 11.2.11.2. Products
  - 11.2.11.3. Financials (Based on Availability)
  - 11.2.11.4. Recent Developments
  - 11.2.11.5. Strategies
  - 11.2.11.6. SWOT,Etc.

Product Code: FBI112985

List of Tables

Table 1: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
Table 2: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Technique, 2019-2032
Table 3: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2019-2032
Table 4: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2019-2032
Table 5: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2019-2032
Table 6: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Sample Type, 2019-2032
Table 7: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Application, 2019-2032
Table 8: Global Lab-based IVD Market Revenue (USD billion) Forecast, by End-user, 2019-2032
Table 9: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Region, 2019-2032
Table 10: North America Lab-based IVD Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
Table 11: North America Lab-based IVD Market Revenue (USD billion) Forecast, by Technique, 2019-2032
Table 12: North America Lab-based IVD Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2019-2032
Table 13: North America Lab-based IVD Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2019-2032
Table 14: North America Lab-based IVD Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2019-2032
Table 15: North America Lab-based IVD Market Revenue (USD billion) Forecast, by Sample Type, 2019-2032
Table 16: North America Lab-based IVD Market Revenue (USD billion) Forecast, by Application, 2019-2032
Table 17: North America Lab-based IVD Market Revenue (USD billion) Forecast, by End-user, 2019-2032
Table 18: North America Lab-based IVD Market Revenue (USD billion) Forecast, By Country, 2019-2032
Table 19: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
Table 20: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by Technique, 2019-2032
Table 21: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2019-2032
Table 22: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2019-2032
Table 23: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2019-2032
Table 24: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by Sample Type, 2019-2032
Table 25: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by Application, 2019-2032
Table 26: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by End-user, 2019-2032
Table 27: Europe Lab-based IVD Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
Table 28: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
Table 29: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by Technique, 2019-2032
Table 30: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2019-2032
Table 31: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2019-2032
Table 32: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2019-2032
Table 33: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by Sample Type, 2019-2032
Table 34: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by Application, 2019-2032
Table 35: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by End-user, 2019-2032
Table 36: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
Table 37: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
Table 38: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by Technique, 2019-2032
Table 39: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2019-2032
Table 40: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2019-2032
Table 41: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2019-2032
Table 42: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by Sample Type, 2019-2032
Table 43: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by Application, 2019-2032
Table 44: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by End-user, 2019-2032
Table 45: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
Table 46: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
Table 47: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by Technique, 2019-2032
Table 48: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2019-2032
Table 49: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2019-2032
Table 50: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2019-2032
Table 51: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by Sample Type, 2019-2032
Table 52: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by Application, 2019-2032
Table 53: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by End-user, 2019-2032
Table 54: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

Figure 1: Global Lab-based IVD Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
Figure 2: Global Lab-based IVD Market Value Share (%), by Product Type, 2024 & 2032
Figure 3: Global Lab-based IVD Market Value Share (%), by Technique, 2024 & 2032
Figure 4: Global Lab-based IVD Market Value Share (%), by Sample Type 2024 & 2032
Figure 5: Global Lab-based IVD Market Value Share (%), by Application, 2024 & 2032
Figure 6: Global Lab-based IVD Market Value Share (%), by End-user, 2024 & 2032
Figure 7: Global Lab-based IVD Market Value (USD billion), by Region, 2024 & 2032
Figure 8: North America Lab-based IVD Market Value (USD billion), by Product Type, 2024 & 2032
Figure 9: North America Lab-based IVD Market Value Share (%), by Product Type, 2024
Figure 10: North America Lab-based IVD Market Value (USD billion), by Technique, 2024 & 2032
Figure 11: North America Lab-based IVD Market Value Share (%), by Technique, 2024
Figure 12: North America Lab-based IVD Market Value (USD billion), by Sample Type, 2024 & 2032
Figure 13: North America Lab-based IVD Market Value Share (%), by Sample Type, 2024
Figure 14: North America Lab-based IVD Market Value (USD billion), by Application, 2024 & 2032
Figure 15: North America Lab-based IVD Market Value Share (%), by Application, 2024
Figure 16: North America Lab-based IVD Market Value (USD billion), by End-user, 2024 & 2032
Figure 17: North America Lab-based IVD Market Value Share (%), by End-user, 2024
Figure 18: North America Lab-based IVD Market Value (USD billion), By Country, 2024 & 2032
Figure 19: North America Lab-based IVD Market Value Share (%), By Country, 2024
Figure 20: Europe Lab-based IVD Market Value (USD billion), by Product Type, 2024 & 2032
Figure 21: Europe Lab-based IVD Market Value Share (%), by Product Type, 2024
Figure 22: Europe Lab-based IVD Market Value (USD billion), by Technique, 2024 & 2032
Figure 23: Europe Lab-based IVD Market Value Share (%), by Technique, 2024
Figure 24: Europe Lab-based IVD Market Value (USD billion), by Sample Type, 2024 & 2032
Figure 25: Europe Lab-based IVD Market Value Share (%), by Sample Type, 2024
Figure 26: Europe Lab-based IVD Market Value (USD billion), by Application, 2024 & 2032
Figure 27: Europe Lab-based IVD Market Value Share (%), by Application, 2024
Figure 28: Europe Lab-based IVD Market Value (USD billion), by End-user, 2024 & 2032
Figure 29: Europe Lab-based IVD Market Value Share (%), by End-user, 2024
Figure 30: Europe Lab-based IVD Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
Figure 31: Europe Lab-based IVD Market Value Share (%), By Country/ Sub-region, 2024
Figure 32: Asia Pacific Lab-based IVD Market Value (USD billion), by Product Type, 2024 & 2032
Figure 33: Asia Pacific Lab-based IVD Market Value Share (%), by Product Type, 2024
Figure 34: Asia Pacific Lab-based IVD Market Value (USD billion), by Technique, 2024 & 2032
Figure 35: Asia Pacific Lab-based IVD Market Value Share (%), by Technique, 2024
Figure 36: Asia Pacific Lab-based IVD Market Value (USD billion), by Sample Type, 2024 & 2032
Figure 37: Asia Pacific Lab-based IVD Market Value Share (%), by Sample Type, 2024
Figure 38: Asia Pacific Lab-based IVD Market Value (USD billion), by Application, 2024 & 2032
Figure 39: Asia Pacific Lab-based IVD Market Value Share (%), by Application, 2024
Figure 40: Asia Pacific Lab-based IVD Market Value (USD billion), by End-user, 2024 & 2032
Figure 41: Asia Pacific Lab-based IVD Market Value Share (%), by End-user, 2024
Figure 42: Asia Pacific Lab-based IVD Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
Figure 43: Asia Pacific Lab-based IVD Market Value Share (%), By Country/ Sub-region, 2024
Figure 44: Latin America Lab-based IVD Market Value (USD billion), by Product Type, 2024 & 2032
Figure 45: Latin America Lab-based IVD Market Value Share (%), by Product Type, 2024
Figure 46: Latin America Lab-based IVD Market Value (USD billion), by Technique, 2024 & 2032
Figure 47: Latin America Lab-based IVD Market Value Share (%), by Technique, 2024
Figure 48: Latin America Lab-based IVD Market Value (USD billion), by Sample Type, 2024 & 2032
Figure 49: Latin America Lab-based IVD Market Value Share (%), by Sample Type, 2024
Figure 50: Latin America Lab-based IVD Market Value (USD billion), by Application, 2024 & 2032
Figure 51: Latin America Lab-based IVD Market Value Share (%), by Application, 2024
Figure 52: Latin America Lab-based IVD Market Value (USD billion), by End-user, 2024 & 2032
Figure 53: Latin America Lab-based IVD Market Value Share (%), by End-user, 2024
Figure 54: Latin America Lab-based IVD Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
Figure 55: Latin America Lab-based IVD Market Value Share (%), By Country/ Sub-region, 2024
Figure 56: Middle East & Africa Lab-based IVD Market Value (USD billion), by Product Type, 2024 & 2032
Figure 57: Middle East & Africa Lab-based IVD Market Value Share (%), by Product Type, 2024
Figure 58: Middle East & Africa Lab-based IVD Market Value (USD billion), by Technique, 2024 & 2032
Figure 59: Middle East & Africa Lab-based IVD Market Value Share (%), by Technique, 2024
Figure 60: Middle East & Africa Lab-based IVD Market Value (USD billion), by Sample Type, 2024 & 2032
Figure 61: Middle East & Africa Lab-based IVD Market Value Share (%), by Sample Type, 2024
Figure 62: Middle East & Africa Lab-based IVD Market Value (USD billion), by Application, 2024 & 2032
Figure 63: Middle East & Africa Lab-based IVD Market Value Share (%), by Application, 2024
Figure 64: Middle East & Africa Lab-based IVD Market Value (USD billion), by End-user, 2024 & 2032
Figure 65: Middle East & Africa Lab-based IVD Market Value Share (%), by End-user, 2024
Figure 66: Middle East & Africa Lab-based IVD Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
Figure 67: Middle East & Africa Lab-based IVD Market Value Share (%), By Country/ Sub-region, 2024
Figure 68: Global Lab-based IVD Market Share (%), By Company, 2024

Lab-based IVD Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Description

Table of Contents

List of Tables

Growth Factors of lab-based in vitro diagnostics (IVD) Market

Regional Insights

Table of Content

1. Introduction

2. Executive Summary

3. Market Dynamics

4. Key Insights

5. Global Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

6. North America Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

7. Europe Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

8. Asia Pacific Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

9. Latin America Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

10. Middle East & Africa Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

11. Competitive Analysis

List of Tables

List of Figures